Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
Preimplantation Genetic Testing Market Size & Growth Forecast 2026–2035, By Segments (Procedure, Product, Technology, End-Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Base Year Value (2025)
USD 955.24 Million
CAGR (2026-2035)
10.3%
Forecast Year Value (2035)
USD 2.55 Billion
Historical Data Period
2022-2025
Largest Region
Europe
Forecast Period
2026-2035
Preimplantation Genetic Testing Market Intelligence Snapshot:
-
Regional Market Dynamics:
- Europe leads with 36.73% share due to mature IVF infrastructure, widespread fertility clinics, and routine integration of advanced genetic testing within assisted reproduction workflows.
- Asia Pacific grows at 11.54% CAGR driven by rising fertility treatment uptake, expanding reproductive medicine capacity, and increasing integration of genetic testing into IVF programs.
-
Segment Momentum:
- Preimplantation Genetic Diagnosis held a 74.05% share in 2025 because it directly addresses the need to identify known inherited genetic disorders before embryo transfer, supporting targeted reproductive decision-making.
- Instrument demand is rising as fertility centers and laboratories expand in-house testing capabilities, upgrade infrastructure, and adopt more integrated platforms to improve workflow efficiency and handle growing testing volumes.
-
Market Expansion Drivers:
- Rising prevalence of genetic disorders increasing demand for embryo-level genetic screening in IVF procedures.
- Advancements in non-invasive genetic testing improving embryo viability assessment and IVF success rates.
- Expanding assisted reproductive technology adoption driving demand for comprehensive embryo selection solutions.
-
Leading Market Participants:
Prominent companies in the preimplantation genetic testing market include Illumina, Inc. (United States), Thermo Fisher Scientific Inc. (United States), CooperSurgical, Inc. (United States), Natera, Inc. (United States), Quest Diagnostics Incorporated (United States), Laboratory Corporation of America Holdings (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Igenomix S.L. (Spain), Genea Limited (Australia).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2025 Market Size: USD 955.24 Million
- 2026 Market Size: USD 15.2 billion
- Projected Market Size: USD 2.55 Billion by 2035
- Growth Forecasts: 10.3% CAGR (2026-2035)
-
Regional and Segment Outlook:
- Leading Regional Market: Europe
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Preimplantation Genetic Diagnosis (Procedure) | Reagents and Consumables (Product) | Polymerase Chain Reaction (PCR) (Technology) | Hospitals (End-Use) | Aneuploidy Screening (Application)
- Emerging Opportunity Segment: Preimplantation Genetic Screening (Procedure) | Instruments (Product) | Next Generation Sequencing (NGS) (Technology) | Hospitals (End-Use) | Aneuploidy Screening (Application)
Market Growth Drivers and Industry Trends
Rising prevalence of genetic disorders increasing demand for embryo-level genetic screening in IVF proceduresAs awareness of inherited conditions grows among prospective parents and fertility specialists, embryo-level screening is becoming a more routine decision point in IVF treatment rather than an optional add-on. In the preimplantation genetic testing market, This trends demand toward testing workflows that can identify chromosomal abnormalities and single-gene disorders before transfer, helping clinics reduce the likelihood of failed implantation, miscarriage, or transmission of known familial conditions. The practical effect is stronger integration of genetic counseling, laboratory testing, and embryo selection into standard fertility care pathways, reinforcing market demand from patients seeking greater reproductive certainty during high-cost IVF cycles.
Advancements in non-invasive genetic testing improving embryo viability assessment and IVF success rates
Progress in non-invasive testing methods is influencing adoption by reducing dependence on embryo biopsy, a step that has traditionally required specialized handling and raised concerns about procedural impact on fragile embryos. For the preimplantation genetic testing market, improved analysis of genetic material from embryo culture media supports broader use of testing among clinics that want more scalable and less invasive assessment tools while still strengthening embryo selection decisions. This changes purchasing and adoption behavior in practice: fertility centers become more willing to incorporate genetic screening into routine protocols when it aligns with laboratory efficiency, patient comfort, and the clinical goal of improving transfer outcomes.
Expanding assisted reproductive technology adoption driving demand for comprehensive embryo selection solutions
As more patients enter fertility treatment through delayed parenthood, infertility diagnosis, and broader use of assisted reproductive technology, clinics face greater pressure to improve cycle efficiency and maximize the chances of successful pregnancy from each transfer. That dynamic is driving demand for more comprehensive embryo selection tools, with the preimplantation genetic testing market benefiting from its role in helping clinicians prioritize embryos with stronger implantation potential and lower genetic risk. In practice, rising ART volumes encourage fertility providers to invest in integrated testing capabilities, specialized laboratory partnerships, and more standardized selection protocols, contributing to market size growth by embedding genetic assessment more deeply into routine IVF decision-making.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of genetic disorders increasing demand for embryo-level genetic screening in IVF procedures | 2.00% | High | North America, Europe | High | Near Term |
| Advancements in non-invasive genetic testing improving embryo viability assessment and IVF success rates | 1.80% | High | Europe, Asia Pacific | Medium | Mid Term |
| Expanding assisted reproductive technology adoption driving demand for comprehensive embryo selection solutions | 1.50% | Moderate | Europe, Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
Europe
36.73% Market Share in 2025
Europe held the leading regional position in 2025, accounting for a 36.73% share of the preimplantation genetic testing market. This leadership is backed by the region’s established assisted reproductive technology infrastructure, broad availability of specialized fertility clinics, and routine integration of advanced genetic screening into IVF workflows. In practice, this means patients and providers can access testing through mature clinical networks with experienced embryology and genetics teams, which helps sustain procedure volumes and reinforces adoption across treatment centers.
Asia Pacific is projected to expand at an 11.54% CAGR over the forecast period in the preimplantation genetic testing market, driven by rising uptake of fertility treatment and the ongoing buildout of reproductive medicine capabilities across the region. Growth is accelerating as more clinics incorporate genetic testing into standard IVF pathways and as access improves in large patient-population markets where demand for fertility care is increasing. The region’s momentum is closely tied to practical expansion in service capacity, stronger clinical adoption, and a growing base of patients entering structured fertility treatment programs.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Emerging | Nascent |
| Cost-Sensitive Region | Low | Medium | Low | High | High |
| Regulatory Environment | Supportive | Neutral | Restrictive | Neutral | Neutral |
| Demand Drivers | Strong | Moderate | Strong | Moderate | Weak |
| Development Stage | Developed | Developing | Developed | Emerging | Emerging |
| Adoption Rate | High | Medium | High | Medium | Low |
| New Entrants / Startups | Dense | Moderate | Dense | Sparse | Sparse |
| Macro Indicators | Strong | Stable | Stable | Weak | Weak |
Key Country Insights
The U.S. preimplantation genetic testing market benefits from widespread integration of genetic testing within assisted reproductive services. Fertility centers across the U.S. continue investing in laboratory capabilities and genetic counseling to support informed embryo selection and personalized reproductive care.
Japan expands the use of preimplantation genetic testing through specialized fertility centers focused on improving embryo assessment. Japanese providers strengthen laboratory accuracy and patient counseling while aligning testing practices with evolving clinical guidance.
South Korea advances preimplantation genetic testing through technologically sophisticated fertility clinics and molecular diagnostic capabilities. South Korean providers emphasize laboratory efficiency, embryo assessment quality, and integrated reproductive treatment pathways for prospective parents.
Germany applies preimplantation genetic testing within a carefully regulated reproductive medicine framework. German fertility providers prioritize laboratory quality, clinical compliance, and multidisciplinary collaboration to ensure responsible implementation of genetic testing services.
France incorporates preimplantation genetic testing within structured fertility care supported by clinical oversight and genetic counseling. French providers focus on appropriate patient selection, laboratory consistency, and informed reproductive decision-making throughout treatment pathways.
Italy strengthens preimplantation genetic testing through specialized reproductive medicine centers with expanding molecular diagnostic expertise. Italian clinics prioritize coordinated clinical evaluation, laboratory reliability, and personalized fertility strategies to support complex reproductive care needs.
Segment Leadership and Growth Trends
Preimplantation Genetic Diagnosis held the dominant position in the preimplantation genetic testing market in 2025, accounting for a 74.05% share. Its dominance is sustained by the direct clinical need to identify specific inherited genetic disorders before embryo transfer, making it a core procedure in cases where intended parents carry known single-gene or chromosomal conditions. This established clinical use case supports consistent demand, as Preimplantation Genetic Diagnosis is closely tied to targeted reproductive decision-making rather than optional screening expansion.
Preimplantation Genetic Screening is emerging as the fastest-growing procedure in the preimplantation genetic testing market because fertility care is increasingly incorporating broader embryo assessment into routine IVF workflows. Its momentum is reinforced through rising interest in improving embryo selection efficiency when no specific inherited disorder has already been identified, which gives it wider applicability across a broader patient base than highly targeted diagnostic testing. As clinics seek more standardized and scalable testing approaches, Preimplantation Genetic Screening is gaining traction relative to procedure options tied primarily to known genetic risk.
Product Segment Analysis: Reagents and Consumables (Largest Segment) vs Instruments (Fastest-Growing Segment)
In 2025, Reagents and Consumables represented the largest product category in the preimplantation genetic testing market with a 53% share. This leadership reflects the recurring nature of testing workflows, where every cycle depends on a steady volume of assay kits, sample preparation materials, and other laboratory consumables. Demand remains anchored in routine laboratory operations, giving Reagents and Consumables a durable advantage over products purchased less frequently, since ongoing test throughput translates directly into repeat consumption.
Instruments are the fastest-growing product segment in the preimplantation genetic testing market as laboratories and fertility centers continue to strengthen in-house testing capacity and modernize workflow efficiency. Growth is being reinforced through the practical need for more capable and integrated testing platforms that can handle rising procedural volumes with improved consistency. Compared with consumables, which grow in line with routine usage, instruments gain momentum when providers expand infrastructure, upgrade technology, or bring more advanced testing functions into regular clinical practice.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Procedure | Preimplantation Genetic Diagnosis, Preimplantation Genetic Screening | Preimplantation Genetic Diagnosis | Preimplantation Genetic Screening |
| Product | Reagents and Consumables, Instruments, Software | Reagents and Consumables | Instruments |
| Technology | Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Others | Polymerase Chain Reaction (PCR) | Next Generation Sequencing (NGS) |
| End-Use | Fertility Centers, Hospitals, Diagnostic Centers, Research Centers and Academic Labs | Hospitals | Hospitals |
| Application | Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Others | Aneuploidy Screening | Aneuploidy Screening |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
1. Illumina Inc. (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. CooperSurgical Inc. (United States)
4. Natera Inc. (United States)
5. Quest Diagnostics Incorporated (United States)
6. Laboratory Corporation of America Holdings (United States)
7. F. Hoffmann-La Roche Ltd. (Switzerland)
8. Igenomix S.L. (Spain)
9. Genea Limited (Australia)
The preimplantation genetic testing market is being shaped by advancements in genomic sequencing, embryo screening accuracy, and reproductive diagnostics. Market participants are investing in next-generation testing platforms and AI-assisted embryo analysis technologies to improve fertility treatment outcomes. Expanding focus on precision reproductive medicine and genetic risk assessment is also accelerating innovation across the market.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GenEmbryomics | May-26 | GenEmbryomics, in partnership with Genomic Prediction, commercialized the XGEN PGT-X™ platform, a whole-genome sequencing solution for IVF workflows. Debuted at PGDIS 2026, this technology provides comprehensive embryo genomic analysis. By launching an early access program at a competitive price point, the company is actively lowering barriers to entry for advanced genetic screening in clinical reproductive medicine. |
| Illumina | Sep-25 | Illumina’s market access division initiated a strategic drive to expand the clinical availability of noninvasive prenatal testing (NIPT) and preimplantation genetic testing (PGT) across Abu Dhabi, UAE. This initiative aims to integrate high-throughput genomic diagnostics into the regional healthcare infrastructure, supporting local fertility clinics and improving the scalability of genetic screening services for patient populations. |
| Juniper Genomics | Jun-25 | Juniper Genomics exited stealth mode with US$4.6 million in seed funding to advance its embryo screening platform. By utilizing integrated whole-genome and transcriptome sequencing, the company targets a broader range of genetic markers than conventional PGT methods. This strategic move aims to improve IVF success rates by providing higher-resolution genomic data for embryo selection and viability assessment. |
| Orchid Health | Jan-24 | Orchid Health launched the first commercially available whole-genome sequencing (WGS) service specifically for detecting monogenic diseases in preimplantation embryos. This service represents a significant technological leap in reproductive genomics, allowing for the precise screening of specific genetic conditions at the embryo stage, which effectively enhances the clinical options available for couples at risk of passing on hereditary disorders. |
| Progenesis | Dec-23 | Progenesis expanded its operational infrastructure by opening a dedicated genetic laboratory in New Delhi and an AI-driven bioinformatics center in Chennai. These facilities significantly increase the company’s regional capacity for IVF-related genetic diagnostics, demonstrating a strategic investment in localizing high-end genomic analysis and bioinformatics capabilities to serve the rapidly growing demand for fertility services in India. |
| Thermo Fisher Scientific | Jul-23 | Thermo Fisher Scientific introduced the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit for its Ion Torrent Genexus Integrated Sequencer. These next-generation sequencing (NGS) tools streamline aneuploidy detection in IVF and ICSI procedures, providing clinics with automated, high-accuracy research-use assays that reduce turnaround times and improve the reliability of genetic screening protocols. |
| Oxford Gene Technology | Jun-23 | Oxford Gene Technology (OGT) established a commercial partnership with Applied Spectral Imaging (ASI) to distribute proprietary cytogenetic imaging and analysis solutions in the UK. This agreement strengthens OGT’s diagnostic portfolio, enabling the integration of advanced digital imaging with existing genetic testing workflows to improve the precision of structural variant detection in complex cytogenetic laboratory environments. |
Frequently Asked Questions
How large is the preimplantation genetic testing market?
In 2026 the market for preimplantation genetic testing is valued at USD 1.04 billion.
How will the preimplantation genetic testing industry grow in terms of size and CAGR by 2035?
Preimplantation Genetic Testing Market size is likely to expand from USD 955.24 million in 2025 to USD 2.55 billion by 2035 posting a CAGR above 10.3% across 2026-2035.
How is expanding assisted reproductive technology adoption influencing investment in the preimplantation genetic testing market?
Growing ART utilization encourages fertility providers to invest in integrated genetic testing capabilities, laboratory partnerships, and standardized embryo selection protocols that improve clinical decision-making and strengthen routine IVF workflows.
Why are non-invasive genetic testing advancements accelerating adoption in the preimplantation genetic testing market?
Non-invasive testing reduces reliance on embryo biopsy while supporting embryo viability assessment. Clinics are more willing to incorporate genetic screening into routine protocols when it improves laboratory efficiency, patient comfort, and embryo selection decisions.
Why does Preimplantation Genetic Diagnosis lead the preimplantation genetic testing market?
Preimplantation Genetic Diagnosis held a 74.05% share in 2025 because it directly addresses the need to identify known inherited genetic disorders before embryo transfer, supporting targeted reproductive decision-making.
Why are instruments the fastest-growing product segment in the preimplantation genetic testing market?
Instrument demand is rising as fertility centers and laboratories expand in-house testing capabilities, upgrade infrastructure, and adopt more integrated platforms to improve workflow efficiency and handle growing testing volumes.
Why does Europe lead the preimplantation genetic testing market?
Europe leads with 36.73% share due to mature IVF infrastructure, widespread fertility clinics, and routine integration of advanced genetic testing within assisted reproduction workflows.
What is driving Asia Pacific growth in the preimplantation genetic testing market?
Asia Pacific grows at 11.54% CAGR driven by rising fertility treatment uptake, expanding reproductive medicine capacity, and increasing integration of genetic testing into IVF programs.
Who holds a significant market share in the preimplantation genetic testing landscape?
Prominent companies in the preimplantation genetic testing market include Illumina, Inc. (United States), Thermo Fisher Scientific Inc. (United States), CooperSurgical, Inc. (United States), Natera, Inc. (United States), Quest Diagnostics Incorporated (United States), Laboratory Corporation of America Holdings (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Igenomix S.L. (Spain), Genea Limited (Australia).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
